In a summary of some recent studies on Covid-19, an arthritis drug cuts the death risk in high-risk patients and heart medications might help prevent Covid-19 blood clots.

Paris-based Sanofi announced that the company’s Phase III PEGASUS clinical trial of rilzabrutinib for pemphigus failed to hit the primary or key secondary endpoints. Sanofi picked up the drug when the company acquired South San Francisco-based Principia Biopharma in August 2020 for $3.68 billion.

Shares of Humanigen plunged in trading after the company announced the U.S. Food and Drug Administration rejected the company’s Emergency Use Authorization request for lenzilumab, a potential treatment for Covid-19.

Syneos Health announced a strategic partnership with Ride Health to offer non-emergency medical transportation (NEMT) to clinical trial participants.

Moderna Inc. is developing a single vaccine that combines a booster dose against Covid-19 with the company’s experimental flu shot.

Heading into fall, with the Covid-19 pandemic surging again and researchers tracking new variants, there is plenty of news. BioSpace takes a look, including several research studies suggesting that some people have unusually strong immunity against Covid-19.

In MacroGenics’ SOPHIA Phase III study in adults with metastatic HER2-positive breast cancer, the biopharmaceutical company’s Margenza plus chemotherapy failed to show a statistically significant advantage when compared to trastuzumab plus chemotherapy in the intent-to-treat population.

The Bill & Melinda Gates Foundation will make a $35 million equity investment in privately owned Exscientia Ltd. to fund the development of antiviral drugs including for the coronavirus, the Oxford-based drug developer said on Sept. 8.

Amgen announced new data from the pivotal NAVIGATOR Phase 3 trial demonstrating that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.

Shares of Adaptimmune Therapeutics skyrocketed after the company announced an agreement to develop and commercialize allogeneic cell therapies for cancer with Genentech.